Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression

T. Redmer, M. Raigel, C. Sternberg, R. Ziegler, C. Probst, D. Lindner, A. Aufinger, T. Limberger, K. Trachtova, P. Kodajova, S. Högler, M. Schlederer, S. Stoiber, M. Oberhuber, M. Bolis, HA. Neubauer, S. Miranda, M. Tomberger, NS. Harbusch, I....

. 2024 ; 23 (1) : 114. [pub] 20240529

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013845

Grantová podpora
LX22NPO5102 Next Generation EU
COMET Österreichische Forschungsförderungsgesellschaft

BACKGROUND: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic drivers, the molecular programs contributing to prostate cancer progression are not fully understood. METHODS: We analyzed JUN expression in clinical prostate cancer samples across different stages and investigated its functional role in a Pten-deficient mouse model. We performed histopathological examinations, transcriptomic analyses and explored the senescence-associated secretory phenotype in the tumor microenvironment. RESULTS: Elevated JUN levels characterized early-stage prostate cancer and predicted improved survival in human and murine samples. Immune-phenotyping of Pten-deficient prostates revealed high accumulation of tumor-infiltrating leukocytes, particularly innate immune cells, neutrophils and macrophages as well as high levels of STAT3 activation and IL-1β production. Jun depletion in a Pten-deficient background prevented immune cell attraction which was accompanied by significant reduction of active STAT3 and IL-1β and accelerated prostate tumor growth. Comparative transcriptome profiling of prostate epithelial cells revealed a senescence-associated gene signature, upregulation of pro-inflammatory processes involved in immune cell attraction and of chemokines such as IL-1β, TNF-α, CCL3 and CCL8 in Pten-deficient prostates. Strikingly, JUN depletion reversed both the senescence-associated secretory phenotype and senescence-associated immune cell infiltration but had no impact on cell cycle arrest. As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth. CONCLUSIONS: Our results suggest that JUN acts as tumor-suppressor and decelerates the progression of prostate cancer by transcriptional regulation of senescence- and inflammation-associated genes. This study opens avenues for novel treatment strategies that could impede disease progression and improve patient outcomes.

Biochemical Institute University of Kiel Kiel 24098 Germany

Bioinformatics Core Unit Swiss Institute of Bioinformatics Bellinzona 6500 TI Switzerland

CEITEC Central European Institute of Technology Masaryk University Brno 625 00 Czech Republic

Center for Biomarker Research in Medicine CBmed GmbH Graz 8010 Austria

Center for Biomarker Research in Medicine Vienna Core Lab2 Medical University of Vienna Vienna 1090 Austria

Charité Universitätsmedizin Berlin Hematology Oncology and Tumor Immunology corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin Berlin 10117 Germany

Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna Vienna 1090 Austria

Comprehensive Cancer Center Medical University Vienna Vienna 1090 Austria

Computational Oncology Unit Department of Oncology Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS Milano 20156 Italy

Department of Biomedical Imaging and Image Guided Therapy Division of Nuclear Medicine Medical University of Vienna Vienna 1090 Austria

Department of Biomedical Sciences Malmö Universitet Malmö 206 06 Sweden

Department of Biosciences and Medical Biology Cancer Cluster Salzburg Paris Lodron University of Salzburg Salzburg 5020 Austria

Department of Cell Biology Charles University Prague Czech Republic and Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University Vestec u Prahy Czech Republic

Department of Molecular Biology Umeå University Umeå 901 87 Sweden

Department of Nutritional Sciences Faculty of Life Sciences University of Vienna Vienna 1090 Austria

Department of Pathology Medical University of Vienna Vienna 1090 Austria

Experimental and Clinical Research Center a cooperation between the MDC and the Charité Berlin Germany

Institute of Animal Breeding and Genetics University of Veterinary Medicine Vienna Vienna 1210 Austria

Institute of Medical Biochemistry University of Veterinary Medicine Vienna Vienna 1210 Austria

Institute of Oncology Research Bellinzona and Faculty of Biomedical Sciences USI Lugano 6500 TI Switzerland

Institute of Physiology Pathophysiology and Biophysics University of Veterinary Medicine Vienna Vienna 1210 Austria

Max Delbrück Center for Molecular Medicine in the Helmholtz Association Group Biology of Malignant Lymphomas Berlin 13125 Germany

Unit of Laboratory Animal Pathology University of Veterinary Medicine Vienna Vienna 1210 Austria

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013845
003      
CZ-PrNML
005      
20240905133926.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-024-02022-x $2 doi
035    __
$a (PubMed)38811984
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Redmer, Torben $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria. torben.redmer@vetmeduni.ac.at
245    10
$a JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression / $c T. Redmer, M. Raigel, C. Sternberg, R. Ziegler, C. Probst, D. Lindner, A. Aufinger, T. Limberger, K. Trachtova, P. Kodajova, S. Högler, M. Schlederer, S. Stoiber, M. Oberhuber, M. Bolis, HA. Neubauer, S. Miranda, M. Tomberger, NS. Harbusch, I. Garces de Los Fayos Alonso, F. Sternberg, R. Moriggl, JP. Theurillat, B. Tichy, V. Bystry, JL. Persson, S. Mathas, F. Aberger, B. Strobl, S. Pospisilova, O. Merkel, G. Egger, S. Lagger, L. Kenner
520    9_
$a BACKGROUND: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic drivers, the molecular programs contributing to prostate cancer progression are not fully understood. METHODS: We analyzed JUN expression in clinical prostate cancer samples across different stages and investigated its functional role in a Pten-deficient mouse model. We performed histopathological examinations, transcriptomic analyses and explored the senescence-associated secretory phenotype in the tumor microenvironment. RESULTS: Elevated JUN levels characterized early-stage prostate cancer and predicted improved survival in human and murine samples. Immune-phenotyping of Pten-deficient prostates revealed high accumulation of tumor-infiltrating leukocytes, particularly innate immune cells, neutrophils and macrophages as well as high levels of STAT3 activation and IL-1β production. Jun depletion in a Pten-deficient background prevented immune cell attraction which was accompanied by significant reduction of active STAT3 and IL-1β and accelerated prostate tumor growth. Comparative transcriptome profiling of prostate epithelial cells revealed a senescence-associated gene signature, upregulation of pro-inflammatory processes involved in immune cell attraction and of chemokines such as IL-1β, TNF-α, CCL3 and CCL8 in Pten-deficient prostates. Strikingly, JUN depletion reversed both the senescence-associated secretory phenotype and senescence-associated immune cell infiltration but had no impact on cell cycle arrest. As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth. CONCLUSIONS: Our results suggest that JUN acts as tumor-suppressor and decelerates the progression of prostate cancer by transcriptional regulation of senescence- and inflammation-associated genes. This study opens avenues for novel treatment strategies that could impede disease progression and improve patient outcomes.
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x patologie $x genetika $x metabolismus $7 D011471
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a lidé $7 D006801
650    12
$a fosfohydroláza PTEN $x genetika $x metabolismus $7 D051059
650    12
$a progrese nemoci $7 D018450
650    12
$a nádorové mikroprostředí $x imunologie $7 D059016
650    _2
$a sekreční fenotyp asociovaný se senescencí $7 D000089262
650    _2
$a protoonkogenní proteiny c-jun $x metabolismus $7 D016755
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a stárnutí buněk $x genetika $7 D016922
650    _2
$a modely nemocí na zvířatech $7 D004195
655    _2
$a časopisecké články $7 D016428
700    1_
$a Raigel, Martin $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Sternberg, Christina $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Biochemical Institute, University of Kiel, Kiel, 24098, Germany
700    1_
$a Ziegler, Roman $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Cell Biology, Charles University, Prague, Czech Republic and Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Vestec u Prahy, Czech Republic
700    1_
$a Probst, Clara $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Lindner, Desiree $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Aufinger, Astrid $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Limberger, Tanja $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Center for Biomarker Research in Medicine (CBmed) Vienna, Core-Lab2, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Trachtova, Karolina $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria $u CEITEC-Central European Institute of Technology, Masaryk University, Brno, 625 00, Czech Republic
700    1_
$a Kodajova, Petra $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria
700    1_
$a Högler, Sandra $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria
700    1_
$a Schlederer, Michaela $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Stoiber, Stefan $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Oberhuber, Monika $u Center for Biomarker Research in Medicine, CBmed GmbH, Graz, 8010, Austria
700    1_
$a Bolis, Marco $u Institute of Oncology Research, Bellinzona and Faculty of Biomedical Sciences, USI, Lugano, 6500, TI, Switzerland $u Computational Oncology Unit, Department of Oncology, Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS, Milano, 20156, Italy $u Bioinformatics Core Unit, Swiss Institute of Bioinformatics, Bellinzona, 6500, TI, Switzerland
700    1_
$a Neubauer, Heidi A $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Institute of Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, 1210, Austria
700    1_
$a Miranda, Sara $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, 1210, Austria
700    1_
$a Tomberger, Martina $u Center for Biomarker Research in Medicine, CBmed GmbH, Graz, 8010, Austria
700    1_
$a Harbusch, Nora S $u Center for Biomarker Research in Medicine, CBmed GmbH, Graz, 8010, Austria
700    1_
$a Garces de Los Fayos Alonso, Ines $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Sternberg, Felix $u Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine Vienna, Vienna, 1210, Austria $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, 1090, Austria
700    1_
$a Moriggl, Richard $u Department of Biosciences and Medical Biology, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, 5020, Austria
700    1_
$a Theurillat, Jean-Philippe $u Institute of Oncology Research, Bellinzona and Faculty of Biomedical Sciences, USI, Lugano, 6500, TI, Switzerland
700    1_
$a Tichy, Boris $u CEITEC-Central European Institute of Technology, Masaryk University, Brno, 625 00, Czech Republic
700    1_
$a Bystry, Vojtech $u CEITEC-Central European Institute of Technology, Masaryk University, Brno, 625 00, Czech Republic
700    1_
$a Persson, Jenny L $u Department of Molecular Biology, Umeå University, Umeå, 901 87, Sweden $u Department of Biomedical Sciences, Malmö Universitet, Malmö, 206 06, Sweden
700    1_
$a Mathas, Stephan $u Charité-Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany $u Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Group Biology of Malignant Lymphomas, Berlin, 13125, Germany $u Experimental and Clinical Research Center (ECRC), a cooperation between the MDC and the Charité, Berlin, Germany
700    1_
$a Aberger, Fritz $u Department of Biosciences and Medical Biology, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, 5020, Austria
700    1_
$a Strobl, Birgit $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, 1210, Austria
700    1_
$a Pospisilova, Sarka $u CEITEC-Central European Institute of Technology, Masaryk University, Brno, 625 00, Czech Republic
700    1_
$a Merkel, Olaf $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Egger, Gerda $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Lagger, Sabine $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria. sabine.lagger@vetmeduni.ac.at
700    1_
$a Kenner, Lukas $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, 1210, Austria. lukas.kenner@meduniwien.ac.at $u Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria. lukas.kenner@meduniwien.ac.at $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, 1090, Austria. lukas.kenner@meduniwien.ac.at $u Center for Biomarker Research in Medicine, CBmed GmbH, Graz, 8010, Austria. lukas.kenner@meduniwien.ac.at $u Comprehensive Cancer Center, Medical University Vienna, Vienna, 1090, Austria. lukas.kenner@meduniwien.ac.at
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 23, č. 1 (2024), s. 114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38811984 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133920 $b ABA008
999    __
$a ok $b bmc $g 2143574 $s 1225711
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 23 $c 1 $d 114 $e 20240529 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
GRA    __
$a LX22NPO5102 $p Next Generation EU
GRA    __
$a COMET $p Österreichische Forschungsförderungsgesellschaft
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace